Assorted News from the Last Week: National Cancer Institute (NCI) is launching the Childhood Cancer – Data Integration for Research, Education, Care, and Clinical Trials
Assorted News from the Last Week: Reporting by the Bureau of Investigative Journalism, in partnership with STAT, reveals that at least a dozen brands of
Assorted News from the Last Week: More about the Food and Drug Administration (FDA) approval of the drug brentuximab vedotin (Adcetris) in combination with chemotherapy
Assorted News from the Last Week: Canadian physicians have successfully used an MRI-guided ultrasound to deliver chemotherapy to an inoperable DIPG brain tumor in a
Assorted News from the Last Week: Day One Biopharmaceuticals shared data recently that a targeted therapy shrank tumors by at least 50% in a majority
Assorted News from the Last Two Weeks: The Centers for Disease Control and Prevention updated its cancer cluster guidelines. “About 85% of children with cancer
Assorted News from the Last Week: FDA approves Brentuximab for high-risk Hodgkin Lymphoma in children and adolescents. The Comprehensive Cancer Survivorship Act was introduced to
Assorted News from the Last Week: For many patients, one of the most antagonizing parts of a hospital visit is paying for parking. Those parking fees
Assorted News from the Last Week: “I’d like to introduce you to Josh. . . Josh, a sound engineer, is also a childhood cancer survivor
Assorted News from the Last Week: CAC2 Member Mary Beth Collins explains the importance of the new FDA approval of Pedmark: “With the FDA’s recent
